FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 333:596-597 August 31, 1995 Number 9 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Henderson, I. C. Related Article by Bonadonna, G. PubMed Citation

To the Editor: Bonadonna et al. (April 6 issue)¹ addressed the effect of drug-induced amenorrhea on the outcomes of 78 premenopausal patients treated with cyclophosphamide, methotrexate, and fluorouracil (CMF) (Table 2 of the article). In 50 patients who had drug-induced amenorrhea and in 28 patients who did not, the rates of 20-year relapse-free survival were 39 percent and 30 percent, respectively. The authors concluded that there was no significant difference in relapse-free survival between these two groups. We estimated the hazard ratio for relapse-free survival between women with drug-induced amenorrhea and those without it from 10 published studies. The hazard . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Klijn, J. G. M., Beex, L. V. A. M., Mauriac, L., van Zijl, J. A., Veyret, C., Wildiers, J., Jassem, J., Piccart, M., Burghouts, J., Becquart, D., Seynaeve, C., Mignolet, F., Duchateau, L. (2000). Combined Treatment With Buserelin and Tamoxifen in Premenopausal Metastatic Breast Cancer: a Randomized Study. JNCI J Natl Cancer Inst 92: 903-911 [Abstract] [Full Text]  
• El-Tamer, M., Homel, P., Braverman, A. S., Wolberg, W. H., Robins, H. I., Goldhirsch, A., Coates, A. S., Colleoni, M., Gelber, R. D., Raffle, A.E., Evans, R. A., Overgaard, M., Rose, C., Mouridsen, H., Ragaz, J., Jackson, S. M., Spinelli, J. J., Hellman, S. (1998). Radiotherapy and Chemotherapy in High-Risk Breast Cancer. NEJM 338: 329-333 [Full Text]